Charles Honoré is an expert in Oncology at Institut Gustave Roussy (France). As of October 2026, ScienceLeadR ranks Charles Honoré in the top 1% of experts worldwide for Sarcoma. Charles Honoré has authored 279 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 736 (community average: 125). How the SLR is computed.

LeadR Profile

Charles Honoré Institut Gustave Roussy France
736 ScienceLeadR Reputation 736
Network Map

Oncology

Subspecialties: Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026

Source: PubMed

Unicancer R&D

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 279

Citations

Citations: 7 955 1st author: 33 Last author: 25 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
HMGA2::NCOR2 fusion-driven giant cell tumors: Diagnosis and treatment.
PMID 42648418 — cells, genes, giant cell tumors, neoplasms, giant cells, diagnosis, therapeutics, tissues, hematologic diseases
Crit Rev Oncol Hematol20260
Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives.
PMID 42525308 — neoplasms, chondrosarcoma, drug therapy, therapeutics, chemotherapy
Curr Treat Options Oncol20260
Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.
PMID 42291149 — registries, cohort studies, drug therapy, sarcoma, chemotherapy, adjuvant, work, therapeutics, tissues, aids-related complex, chemotherapy
EClinicalMedicine20263
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics.
PMID 41313621 — neoplasms, multiple chronic conditions, sarcoma
Cancer Commun (Lond)20250
Prognostic prediction in soft-tissue sarcomas using deep learning and digital pathology of tumor and margin areas.
PMID 41188261 — telepathology, neoplasms, pathology, sarcoma, deep learning, natural science disciplines, learning, tissues
Sci Rep20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 2
Phase 2 1
Phase 3 1

By status:

Completed 4

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 2

LeadR Networks

Main global connection map